Staging System in Amyotrophic Lateral Sclerosis

Recently two staging systems have been proposed for amyotrophic lateral sclerosis (ALS), based on clinical milestones The King's college clinical staging system (1) and ALS Milano-Torino Staging (ALS-MITOS) (2). Further research to validate and develop an accurate staging system in different populations will improve our understanding of its pathogenesis, disease activity and progression. General objective : To validate the two previously proposed staging system and to test the interest of considering Neurofilament biomarkers in these systems. Specific objectives: 1) To validate the two classification systems in an independent cohort of patients with ALS followed-up in the ALS expert center of Limoges (France) 2) To assess the interest of Nf biomarkers to predict neurological decline

Inclusion Criteria: * ALS cases recruited for retrospectively (between) 2007 to 2016 for the retrospective cohort * ALS cases recruited for prospectively by the ALS expert center of Limoges for one year. Exclusion Criteria: * Previous neurosurgical operations * A recent history of neurotrauma * Peripheral neuropathies * ALS/frontotemporal dementia (ALS/FTD)